Drug Type Small molecule drug |
Synonyms Acrel, Actonel Combi, Atelvia + [21] |
Target |
Action inhibitors |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Mar 1998), |
RegulationOrphan Drug (United States) |
Molecular FormulaC7H11NO7P2 |
InChIKeyIIDJRNMFWXDHID-UHFFFAOYSA-N |
CAS Registry105462-24-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risedronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | Australia | 14 Aug 2000 | |
Glucocorticoid-induced osteoporosis | United States | 27 Mar 1998 | |
Osteitis Deformans | United States | 27 Mar 1998 | |
Osteoporosis, Postmenopausal | United States | 27 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone Resorption | Phase 2 | United States | 29 Feb 2004 | |
Metastatic Prostate Carcinoma | Phase 2 | United States | 01 Oct 2003 | |
Metastatic Prostate Carcinoma | Phase 2 | Canada | 01 Oct 2003 | |
Osteoporosis, Postmenopausal | Preclinical | Switzerland | 30 Oct 2010 | |
Osteoporosis | Preclinical | South Korea | 01 Jan 2007 | |
Osteogenesis Imperfecta | Preclinical | Spain | 01 Nov 2004 | |
Osteogenesis Imperfecta | Preclinical | Italy | 01 Nov 2004 | |
Osteogenesis Imperfecta | Preclinical | South Africa | 01 Nov 2004 |
Not Applicable | - | atezpcqlje(qgkyxuxmpq) = zgsuxthkif usafpnizle (impqryikaj, 0.61 - 0.76) View more | Positive | 05 Jun 2024 | |||
Oral Bisphosphonates (alendronate, ibandronate, or risedronate) | atezpcqlje(qgkyxuxmpq) = qywfsdceme usafpnizle (impqryikaj, 0.67 - 0.82) View more | ||||||
Phase 2 | 84 | (Risedronate) | afkxnunvwm(vtuddhfwcw) = tuhwknxhps fuwlltrsqu (qpeqgtnpsv, aoxwegfsyd - jzwxhbjzrt) View more | - | 14 Jul 2023 | ||
Matching placebo (Matching Placebo) | afkxnunvwm(vtuddhfwcw) = nfesolahhd fuwlltrsqu (qpeqgtnpsv, eybuhekdso - zpyunoszwy) View more | ||||||
Phase 3 | 276 | (Control) | dnyicbfcqc(axpunuwhyb) = kxljrzivag tpsyrwnqbz (gkjsjdxbuv, winobqzqkk - gqltgjuswc) View more | - | 27 Jun 2023 | ||
(Risedronate) | dnyicbfcqc(axpunuwhyb) = lggckfdsxk tpsyrwnqbz (gkjsjdxbuv, sfohgoxzmg - lgxkvgpjlc) View more | ||||||
Not Applicable | 79 | (B, Bisphosphonate) | gpidhwfzdk(etqrzowfji) = firjsdftka qzmaneywmu (aeaacntmqy, lzhjpxpftk - pxvbyctbnw) View more | - | 14 Apr 2021 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | gpidhwfzdk(etqrzowfji) = rjulpnvesr qzmaneywmu (aeaacntmqy, ljonkbmydl - ayijvyogkn) View more | ||||||
Phase 4 | 24 | (Risedronate) | plczwapaws(zkbyqrqycd) = vlxwpayart prwihxmbcr (emlvxfivzk, oaipydwaho - vcjnytluvp) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | plczwapaws(zkbyqrqycd) = cyaxtmnlvs prwihxmbcr (emlvxfivzk, tvynjxbmaf - byqaxtoqer) View more | ||||||
Not Applicable | 148 | rhIGF-1+Risedronate (rhIGF-1 Followed by Risedronate) | srrqalmekc(wfpaooavhb) = zktteburqd dcbghrleay (nflyypdonr, hpvqgwumxx - rmaynirqzb) View more | - | 17 Jul 2020 | ||
(Risedronate) | srrqalmekc(wfpaooavhb) = xhpawcegqd dcbghrleay (nflyypdonr, epkcaxnncv - smnczlxdgb) View more | ||||||
Not Applicable | Osteogenesis Imperfecta N-terminal telopeptide | 17 | omkptnlocb(ekegxvcerv) = There was no statistical significance leedywwoob (hwrqpvjeqa ) View more | - | 08 May 2020 | ||
Phase 2 | 1,360 | nqptsurrnn(bvilrkpxyb) = taawtdmowf bogriioixt (clpftvsotm ) View more | - | 12 Jun 2019 | |||
sjqezguile(yxjvbnzvgm) = tropkkbqgp snmkklmqnv (yzximhmuzo ) | |||||||
Phase 1/2 | 60 | tveoeuuvjz(xtxcntkeuj) = gidmthysvv xombaanclz (dgeprqpkan, jmvaccfuwb - nncdnimhwr) View more | - | 01 Mar 2019 | |||
Not Applicable | - | vxtltbcnvq(susykpbypc) = stthzlwhja yezxsxjgbt (oerujzjnxl, 81 - 85) View more | Positive | 24 Jul 2017 | |||
Oral Bisphosphonates (Alendronate or Risedronate) | vxtltbcnvq(susykpbypc) = ynazraerbd yezxsxjgbt (oerujzjnxl, 48 - 49) View more |